PATENT CLAIM ANALYSIS

Application Number: 15995584
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["530", "387100"]

Abstract:
The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-1, and/or PD-L2 activity (e.g., persistent infectious diseases autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

Claim (Index 61):
The isolated nucleic acid of  claim 58 , wherein the antibody or an antigen-binding fragment thereof, comprises:\n a) a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 34-38, or a sequence with at least about 95% homology to a heavy chain sequence selected from the group consisting of SEQ ID NOs: 34-38; and/or b) a light chain variable region sequence selected from the group consisting of SEQ ID NOs: 39-42, or a sequence with at least about 95% homology to a light chain sequence selected from the group consisting of SEQ ID NOs: 39-42.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 94.0
- Lexical Diversity: 1.57407
- Patent Class: 530.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13120406', '13802172', '14822651', '14248462', '15858963']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7520981489478639
- 35 USC 102 Novelty (BERT): 0.6654163099993723
- Combined Prediction Score: 0.7434299650530147
- Mean Citation Score: 599.014034
- Max Citation Score: 701.8463
- Similarity Product: 621.4540772136687

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test